Tonghua Dongbao (600867) Company Comment: Domestic Insulin Replacement Process Accelerates Performance Forecast Exceeds Expectations
Tonghua Dongbao (600867): Rapid increase in revenue and profit in 4Q23
Tonghua Dongbao (600867): Domestic insulin replacement is expected to accelerate innovation in multiple fields+overseas commercialization to drive long-term growth
Research Report Nuggets | Minsheng Securities: Maintaining Tonghua Dongbao's “Recommended” Rating, Insulin Market Potential Is Huge
Tonghua Dongbao (600867): Daily summary of medical industry enterprises in 2023
Tonghua Dongbao (600867) 2023 Three Quarterly Report Review: Three Generations of Insulin Are Growing Rapidly, and International Business Is Progressing Steadily
Tonghua Dongbao (600867) 2023 Third Quarter Report Review Report: Stable Performance Growth, Steady Release of Profits
Tonghua Dongbao (600867): Insulin business is growing healthily, R&D and overseas travel are progressing smoothly
Tonghua Dongbao (600867) 2023 Three Quarter Report Review: Insulin Sales Continues to Grow, R&D Pipeline Achievements Gradually Realize
Tonghua Dongbao (600867): Steady growth in performance accelerates the internationalization process
Tonghua Dongbao (600867): Revenue and profit are growing under pressure in 3Q23
Tonghua Dongbao (600867) Review of important matters: Cooperating with bodybuilders to enter the US insulin market and accelerate the internationalization process
Tonghua Dongbao (600867) 2023 Interim Report Review: Performance ushered in an inflection point and rapid release of new insulin products
Tonghua Dongbao (600867): Cooperating to enter the US market and continue to accelerate the internationalization process
Tonghua Dongbao (600867): Mining disruptions have basically cleared the innovation pipeline and opened up room for growth
Tonghua Dongbao (600867): Performance is in line with expectations, increasing the layout of diabetes and gout
Tonghua Dongbao (600867): The performance inflection point has reached, and the pipeline harvest is getting closer
Tonghua Dongbao (600867): The impact of mining has been clarified, and the inflection point in performance has arrived
Tonghua Dongbao (600867) In-depth Research Report: Getting Out of Gathering and Getting Better
Tonghua Dongbao (600867): In 2022, insulin was affected by the reduction in collection prices and short-term pressure, and the inflection point of 23Q2 performance is expected to gradually become apparent
No Data